Sterling Pharma completes acquisition of Novartis manufacturing plant in Ireland
The UK-based contract manufacturer Sterling Pharma Solutions has completed a purchase that will give it a manufacturing presence on the other side of the Irish Sea.
Sterling closed its acquisition of an active pharmaceutical ingredient (API) plant in the southern Irish village of Ringaskiddy, Ireland, that once belonged to the Swiss pharma Novartis. The deal, announced in March of last year, will not only give the British CDMO more capacity to produce APIs, but also includes a supply agreement with Novartis to continue to produce ingredients for cardiovascular, immunology and oncology medicines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.